Conventionally, breast cancer has been classified on the basis of the protein expression of the estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor ErbB2/Her2, and expressions of these receptors have been used as clinicopathological variables for treatment decisions [11]. This evidence concerns the gene PGR and breast carcinoma.